CAS OpenIR  > 生化工程国家重点实验室
Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin
Liu, Liping1,2; Zhang, Chun1,2; Li, Zenglan2; Wang, Chunyue1,2; Bi, Jingxiu3; Yin, Shuang1,2,3; Wang, Qi2; Yu, Rong1; Liu, Yongdong2; Su, Zhiguo2
2017-11-01
发表期刊MOLECULAR PHARMACEUTICS
ISSN1543-8384
卷号14期号:11页码:3739-3749
摘要

For the purpose of improving the tumor delivery of doxorubicin (DOX), a kind of peptide-DOXO conjugate was designed and prepared, in which the peptide composed of an albumin-binding domain (ABD) and a tumor-specific internalizing sequence (RGDK or RPARPAR) was conjugated to a (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH). The doxorubicin uptake by lung cancer cell line of A549 evidenced that the conjugates are capable of being internalized through a tumor-specific sequence mediated manner, and the intracellular imaging of distribution in A549 cell demonstrated that the conjugated doxorubicin can be delivered to the cell nucleus. The A549 cell cytotoxicity of peptide-DOXO conjugates was presented with IC50 values and shown in the range of about 9-11 mu M. Pharmacokinetics study revealed that both conjugates exhibited nearly 5.5 times longer half-time than DOX, and about 4 times than DOXO-EMCH. The in vivo growth inhibitions of the two peptide-DOXO conjugates on BALB/c nude mice bearing A549 tumor (47.78% for ABD-RGDK-DOXO and 47.09% for ABD-RPARPAR-DOXO) were much stronger than that of doxorubicin and DOXO-EMCH (24.28% and 25.67% respectively) at a doxorubicin equivalent dose. Besides, the in vivo fluorescence imaging study confirmed that the peptide markedly increased the payload accumulation in tumor tissues and indicated that albumin binding domain fusing tumor-specific sequence effectively enhanced the tumor delivery of doxorubicin and thus improved its therapeutic potency.

关键词Albumin Binding Domain Rgdk Rparpar Doxorubicin Peptide-drug Conjugate
文章类型Article
WOS标题词Science & Technology ; Life Sciences & Biomedicine
DOI10.1021/acs.molpharmaceut.7b00497
收录类别SCI
语种英语
关键词[WOS]Peptide-conjugated Doxorubicin ; Antitumor Efficacy ; Drug-resistance ; Breast-cancer ; Serum-albumin ; Cardiotoxicity ; Release ; Carrier ; Cells ; Platform
WOS研究方向Research & Experimental Medicine ; Pharmacology & Pharmacy
WOS类目Medicine, Research & Experimental ; Pharmacology & Pharmacy
项目资助者National Natural Science Foundation of China(21576267) ; Beijing Natural Science Foundation(2162041) ; National Key Laboratory of Biochemical Engineering(2014KF-05) ; Major State Basic Research Development Program of China(2013CB733604)
WOS记录号WOS:000414820000012
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ipe.ac.cn/handle/122111/23386
专题生化工程国家重点实验室
作者单位1.Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Sichuan, Peoples R China
2.Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China
3.Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia
推荐引用方式
GB/T 7714
Liu, Liping,Zhang, Chun,Li, Zenglan,et al. Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin[J]. MOLECULAR PHARMACEUTICS,2017,14(11):3739-3749.
APA Liu, Liping.,Zhang, Chun.,Li, Zenglan.,Wang, Chunyue.,Bi, Jingxiu.,...&Su, Zhiguo.(2017).Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin.MOLECULAR PHARMACEUTICS,14(11),3739-3749.
MLA Liu, Liping,et al."Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin".MOLECULAR PHARMACEUTICS 14.11(2017):3739-3749.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Albumin Binding Doma(6197KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Liping]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
百度学术
百度学术中相似的文章
[Liu, Liping]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
必应学术
必应学术中相似的文章
[Liu, Liping]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Albumin Binding Domain Fusing R_K-X-X-R_K Sequence for Enhancing Tumor Delivery of Doxorubicin.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。